Evidence map›Paper›PMID 39429723›Full record

ArticleMolecular therapy. Methods & clinical development2024

Aphrodite Georgakopoulou, Chang Li, Hans-Peter Kiem, André Lieber

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Molecular therapy. Methods & clinical development · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Aphrodite GeorgakopoulouUniversity of Washington, Department of Medicine, Division of Medical Genetics, Seattle, WA 98195, USA.
Chang LiUniversity of Washington, Department of Medicine, Division of Medical Genetics, Seattle, WA 98195, USA.
Hans-Peter KiemFred Hutchinson Cancer Center, Seattle, WA, USA.
André LieberUniversity of Washington, Department of Medicine, Division of Medical Genetics, Seattle, WA 98195, USA.

Funding

Approach for in vivo gene delivery into hematopoietic stem cells for hemophilia A therapyR01HL141781 · NHLBI · UNIVERSITY OF WASHINGTON · PI LIEBER, ANDRE MICHAEL · 2018 to 2021
$2.3M
Gates Foundation INV-017692NHLBI NIH HHS R01 HL141781
6 · The paper itself

Abstract

We developed an

Indexed as

adenovirus vectorCD33gemtuzumab ozogamicinGOHbF reactivationhemoglobinopathiesin vivo HSC gene therapy

Identifiers

PMID39429723
PMCPMC11490927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.